CPMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Cannapharmarx's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Cannapharmarx's Dividend Payout Ratio or its related term are showing as below:
As of today (2024-12-14), the Dividend Yield % of Cannapharmarx is 0.00%.
Cannapharmarx's Dividends per Share for the months ended in Sep. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Cannapharmarx's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannapharmarx Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Payout Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Cannapharmarx Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividend Payout Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Cannapharmarx's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Cannapharmarx's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Dividend Payout Ratio | = | Dividends per Share (A: Dec. 2023 ) | / | Earnings per Share (Diluted) (A: Dec. 2023 ) |
= | 0 | / | 0.01 | |
= | 0.00 |
Cannapharmarx's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Sep. 2024 ) | / | EPS without NRI (Q: Sep. 2024 ) |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannapharmarx (OTCPK:CPMD) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Cannapharmarx's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Anthony Michael Panek | director | 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111 |
Dominic Colvin | director, officer: Chief Executive Officer | C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614 |
John Hamilton Cassels | officer: Chief Financial Officer | SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8 |
Richard Dale Orman | director | 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2 |
Andrew Clifford Steedman | officer: Chief Operating Officer | 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9 |
Marc R Branson | director | 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6 |
Gary J Herick | 10 percent owner | 7609 RALSTON ROAD, ARVADA CO 80002 |
James F Samuelson | director | PO BOX 22, NEWPORT BEACH CA 92662 |
Matthew Nicosia | director, 10 percent owner | 2 PARK PLAZA, SUITE 400, IRVINE CA 92614 |
Robert M Liess | director | 2602 W. SAM ALLEN RD., PLANT CITY FL 33565 |
Mathew D Sherwood | director | P.O. BOX 4375, DILLON CO 80435 |
James E Smeeding | director | 4029 GILBERT AVENUE, DALLAS TX 75219 |
Elie M Khalife | director | 9447 E. CROSS CREEK STREET, WICHITA KS 67206 |
Steven J Rule | director | C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069 |
Alexander R Giaquinto | director | 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920 |
From GuruFocus
By ACCESSWIRE • 02-23-2024
By ACCESSWIRE • 06-28-2024
By ACCESSWIRE • 02-16-2024
By ACCESSWIRE • 03-14-2024
By ACCESSWIRE • 03-12-2024
By ACCESSWIRE ACCESSWIRE • 03-21-2023
By ACCESSWIRE ACCESSWIRE • 01-30-2023
By ACCESSWIRE • 05-20-2024
By sperokesalga sperokesalga • 02-22-2023
By ACCESSWIRE ACCESSWIRE • 04-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.